Stock PBYI PUMA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
3.26 USD +0.93% Intraday chart for Puma Biotechnology, Inc. +9.03% -24.71%
06-02 Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041) CI
05-17 Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial RE

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Puma Biotechnology : Corporate Presentation
PU
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
BU
Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)
CI
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
BU
Puma Biotechnology to Join Russell 3000 Index
BU
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
BU
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial
RE
Puma Biotech: Q1 Earnings Snapshot
AQ
Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
Puma Biotechnology Reports First Quarter Financial Results
BU
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024
CI
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
BU
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)
AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise
MT
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
BU
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
CI
Puma Biotechnology : Corporate Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PBYI Stock
  4. News Puma Biotechnology, Inc.